Evidence map›Paper›PMID 31663481›Full record

ReviewCurrent HIV research2019

The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley.

Roberto De La Garza, Hansapani Rodrigo, Francisco Fernandez, Upal Roy

Open access · bronzeAbstract readReview
In one paragraph

Review in Current HIV research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Involvement of TGFβ signaling pathway in oxidative stress and diabetic retinopathy.Archives of clinical and experimental ophthalmology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Roberto De La GarzaDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, Texas, United States.
Hansapani RodrigoSchool of Mathematical and Statistical Sciences, University of Texas Rio Grande Valley, Edinburg, Texas, United States.
Francisco FernandezDepartment of Psychiatry, School of Medicine, University of Texas Rio Grande Valley, Harlingen, Texas, United States.
Upal RoyDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, Texas, United States.
The University of Texas Rio Grande Valley · US

Funding

Nanodiamond based anti-HIV drug delivery targeted towards the brainR15NS108815 · NINDS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI ROY, UPAL · 2018 to 2018
$433k
NINDS NIH HHS R15 NS108815
6 · The paper itself

Abstract

The Human Immunodeficiency Virus (HIV-1) infection remains a persistent predicament for the State of Texas, ranking seventh among the most documented HIV cases in the United States. In this regard, the Rio Grande Valley (RGV) in South Texas is considered as one of the least investigated areas of the state with respect to HIV infection and HIV associated comorbidities. Considering the 115% increase in average HIV incidence rates per 100,000 within the RGV from 2007-2015, it is worth characterizing this population with respect to their HIV-1 infection, HIV-1 Associated Neurocognitive Disorders (HAND), and the association of treatment with combined antiretroviral therapy (cART). Moreover, the increased rate of Type-2 Diabetes (T2D) in the RGV population is intertwined with that of HIV-1 infection facing challenges due to the lack of knowledge about prevention to inadequate access to healthcare. Hence, the role of T2D in the development of HAND among the people living with HIV (PLWH) in the RGV will be reviewed to establish a closer link between T2D and HAND in cART-treated patients of the RGV.

Indexed as

Anti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveDiabetes Mellitus, Type 2Disease SusceptibilityGeography, MedicalHIV InfectionsHumansIncidenceNeurocognitive DisordersPopulation SurveillancePrevalenceTexasAnti-Retroviral AgentsBraincARTCNSdiabetesHANDHispanicsHIV-1incidence rateMMSEMoCAprevalence rate.T2D

Identifiers

PMID31663481
PMCPMC7334829
OpenAlexW2982325485

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.